ReviewCurrent opinion in infectious diseases2025
Resurgence of Mycoplasma pneumoniae infections in children: emerging challenges and opportunities.
Review in Current opinion in infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Seasonal Distribution, Virus-Specific Hematologic Profiles, and Predictors of Hospitalization in Children with Respiratory Viral Infections.Children (Basel, Switzerland) · 2026Article
- High-Dimensional Immune Profiling Reveals Innate-Adaptive Rebalancing and Subpopulation Trajectories in Pediatric SevereDiagnostics (Basel, Switzerland) · 2026Article
- Research progress on detection technologies for Mycoplasma pneumoniae.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Review
- Efficacy and safety of Doxycycline versus Macrolides forBMJ open · 2026Article
- Epidemic features and clinical analysis of pediatricTranslational pediatrics · 2026Article
- Emergence of Clinically Macrolide-UnresponsiveAntibiotics (Basel, Switzerland) · 2026Article
- A study on the correlation between intestinal flora characteristics and serum zinc and iron levels in paediatric patients with mycoplasma pneumoniae pneumonia.BMC pediatrics · 2026Article
- Clinical characteristics and risk factors of necrotizing pneumonia secondary to severe pneumonia in children.Frontiers in pediatrics · 2026Article
- Economic burden ofFrontiers in public health · 2026Article
- Impact of early corticosteroid therapy on short-term pulmonary function and clinical outcomes in children with severeFrontiers in pediatrics · 2026Article
- Doxycycline for Macrolide-ResistantInfection and drug resistance · 2026Review
- Genomic surveillance of the pneumonia outbreak caused byFrontiers in cellular and infection microbiology · 2026Article
- Epidemiology and co-infection networks of pediatric respiratory pathogens in eastern China after COVID-19 restriction relaxation: a retrospective study.Frontiers in cellular and infection microbiology · 2026Article
- Risk factors for multiple bronchoalveolar lavage procedures in children with severe or refractory Mycoplasma pneumoniae pneumonia.Jornal de pediatriaArticle
- Antibody Serologies and Diagnostic Considerations in Reactive Infectious Mucocutaneous Eruption.Pediatric dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTo summarize recent advances in Mycoplasma pneumoniae epidemiology, pathophysiology, diagnostics, and treatment, since the 2023-2024 global resurgence of M. pneumoniae following the COVID-19 pandemic has provided new insights. RECENT
findingsThe remarkably prolonged reduction of M. pneumoniae infections during COVID-19-related nonpharmaceutical interventions has shed new light on M. pneumoniae transmission, both on an individual and a global level. M. pneumoniae epidemiology showed striking differences in comparison with other respiratory pathogens, including RSV and pneumococcus. We discuss the possible mechanisms behind the delayed resurgence, including waning immunity and the persistence of M. pneumoniae reservoirs. There have been contrasting reports on disease severity with notable differences in severity between children and adults, with young adults showing marked vulnerability. The inability of M. pneumoniae diagnostic tests to differentiate between infection and carriage poses a continuing challenge: in daily clinical practice as well as in the interpretation of study results. Furthermore, several studies report safety and utility for tetracyclines and fluoroquinolones as treatment alternatives to macrolide antibiotics. SUMMARY: The global resurgence of M. pneumoniae following COVID-19 pandemic restrictions has provided a unique opportunity to study its epidemiology and pathophysiology, which has advanced our understanding of M. pneumoniae infections in children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.